Johnson & Johnson announced it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech.
The acquisition of V-Wave extends Johnson & Johnson MedTech’s position in cardiovascular disease and provides an even greater opportunity to tackle heart failure, one of the most pressing unmet medical needs in healthcare today. It further accelerates the Company’s shift into high-growth and high-opportunity markets and complements a well-rounded medical technology portfolio of leading platforms that address coronary artery disease and peripheral artery disease, heart recovery, and atrial fibrillation. It will also deepen the Company’s relationships with structural interventional cardiologists and heart failure specialists.
Also Read: Rob Renzi Joins Catalyst Solutions as Chief Growth Officer
Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech. V-Wave’s novel implantable device, the Ventura® Interatrial Shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”
Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
SOURCE: Businesswire